The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A relatively low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. The Company has several strategic collaborations that are expediting the development in a highly-efficient manner and by pursuing an efficient regulatory strategy this presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500k to $1MM to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could ultimately yield the balance of funding to fully deploy a commercial version of the technology.

NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.